Reabold Resources Regulatory News (RBD)

2 Dec 2005 07:01

Adventis Group PLC02 December 2005 For Release01 December 2005 ADVENTIS GROUP PLC: CONTRACT GAIN Affiniti to launch new product for Roche Adventis Group plc, the specialist multi-media marketing and advertising agency,announces that its subsidiary, Affiniti have just won a pitch to handle thelaunch of MabThera(R) (rituximab), for a non-cancer indication for anundisclosed sum. This is the agency's third win at Roche in two years andaccording to Roche, it was a unanimous decision to appoint Affiniti. The drug is expected to receive regulatory approval during 2006. Commenting, Affiniti MD, Stuart Tennant, said: "Everyone in the agency isdelighted. The winning of this pitch is just reward for the time Affiniti spenttalking to specialist hospital consultants and nurses in order to reallyunderstand the issues of this chronic disease. We are very busy at the momentand are looking to add new staff over the coming six months to broaden ourcapability." Ends For more information, contact: Adventis Group PlcCharles Philpot, Managing Directorcjphillpot@adventis.co.uk 020 7034 4750 Binns & Co PRPeter BinnsPeter.binns@binnspr.co.uk 020 7786 9600 Seymour Pierce LimitedJohn Depasqualejdp@seymourpierce.com 020 7107 8030 Editor's Note: Adventis Group plc acquired Affiniti (UK) LTD, a media planner and buyer lastMarch. In additon to Roche. Affiniti's clients include Allergan, Sanofi PasteurMSD, Chiron Vaccines, Eden Biopharm, Leo Pharma, NAPP and Serono. This information is provided by RNS The company news service from the London Stock Exchange